Ayurvedic Treatment for Psoriasis

Psoriasis, a chronic autoimmune condition, is more than just a skin disorder. Its red, scaly patches, persistent inflammation, and itching can significantly affect one’s quality of life—physically, emotionally, and socially (Griffiths & Barker, 2007; Takeshita et al., 2017). For many, it feels like a never-ending struggle, with conventional treatments providing only temporary relief.

At EliteAyurveda, we see Psoriasis not as a life sentence but as a call to restore balance. Our holistic, personalized Ayurvedic approach aims to heal from within, addressing the root cause and empowering patients to achieve long-term remission and improved well-being (Frawley, 2000; Lad, 2002).

Ayurveda's Approach to Psoriasis Treatment
Ayurveda’s Approach to Psoriasis Treatment

The Reality of Conventional Treatments: Symptom Suppression Over Healing

Modern medicine primarily manages Psoriasis symptoms through treatments like corticosteroids, immunosuppressants, and biologics (Griffiths & Barker, 2007). While these can offer relief, they often come at a cost:

  1. Side Effects: Long-term use of steroids and immunosuppressants can lead to thinning skin, liver damage, weakened immunity, and other complications.
  2. Dependency: Patients frequently find themselves increasing dosages or switching medications as effectiveness diminishes.
  3. Frequent Flare-Ups: By focusing solely on symptoms, conventional treatments often fail to address the root causes, leading to recurring flare-ups.
  4. Mental Health Toll: The visible nature of Psoriasis often leads to anxiety, depression, and a diminished quality of life (Takeshita et al., 2017).

While these treatments are invaluable for acute episodes, they are not designed for long-term healing. This is where Ayurveda excels, offering a sustainable, side-effect-free alternative (Pole, 2013).

Ayurveda’s Perspective on Psoriasis

In Ayurveda, Psoriasis is known as “Kitibha” or “Ekakushtha,” classified under chronic skin disorders caused by imbalances in the Pitta and Vata doshas and the buildup of toxins (Ama) (Sharma et al., 2007). These imbalances interfere with the body’s metabolic processes, leading to chronic inflammation and the rapid turnover of skin cells.

Ayurvedic Insights on Psoriasis:

  • Vata Imbalance: Contributes to dryness, scaling, and itching.
  • Pitta Imbalance: Leads to redness, inflammation, and burning sensations.
  • Ama (Toxins): Accumulates due to impaired digestion and lifestyle factors, exacerbating symptoms.

Ayurveda views Psoriasis as a systemic issue that requires a holistic treatment plan targeting both the skin and internal imbalances (Frawley, 2000).

Dispelling Myths: Psoriasis Is Treatable

One of the most damaging myths about Psoriasis is that it is untreatable. This misconception arises from treatments that target only surface symptoms without addressing the underlying imbalances. Ayurveda takes a different path, focusing on restoring the body’s natural harmony and achieving long-term remission.

Dr. Adil Moulanchikkal, Lead Ayurveda Skin Specialist at EliteAyurveda, notes:

“Psoriasis is not merely a skin ailment; it mirrors internal disharmony. Ayurveda’s emphasis on holistic balance offers a route to genuine healing and sustained remission.”

A Holistic Ayurvedic Approach to Healing

At EliteAyurveda, our goal is to treat the individual, not just the disease. Each patient’s unique constitution (Prakriti) and imbalances (Vikruti) guide the treatment plan, ensuring a personalized journey toward relief, enhanced well-being, and fewer flare-ups.

Our Comprehensive Treatment Plan Includes:

  1. Herbal Medications
    • Proprietary in-house formulations crafted to calm inflammation, detoxify the body, and stabilize immune responses (Frawley, 2000).
  2. Personalized Dietary Guidance
    • Emphasizing foods that support digestion, boost immunity, and minimize triggers for Psoriasis flare-ups.
  3. Detoxification Therapies
    • Mild yet effective cleanses to remove Ama and reset bodily functions, preventing toxin buildup (Sharma et al., 2007).
  4. Stress Management
    • Techniques like yoga, meditation, and deep-breathing exercises to reduce stress and inflammation.
  5. Lifestyle Modifications
    • Practical advice to protect the skin, maintain hydration, and avoid environmental triggers.
  6. Ongoing Support and Monitoring
    • Regular follow-ups to track progress, adjust therapies, and ensure sustainable remission.

Why Choose EliteAyurveda?

At EliteAyurveda, we focus on more than just suppressing symptoms—we strive for true healing. Here’s why patients trust us:

  1. Root-Cause Healing: We address the fundamental imbalances driving Psoriasis, not just the external lesions.
  2. Personalized Care: Every treatment regimen is tailored to the patient’s doshic constitution and specific concerns.
  3. Natural, Safe Solutions: Our herbal medications avoid the side effects associated with conventional drugs.
  4. Holistic Wellness: By integrating physical, emotional, and lifestyle elements, we foster comprehensive recovery.
  5. Established Expertise: With over 15 years of experience, our Ayurvedic treatments are proven to help patients achieve lasting remission.

Real Stories, Real Results

Many of our patients have experienced life-changing transformations. From clearer skin to regained confidence, their journeys stand as a testament to the power of a personalized, holistic approach.

One patient shared:

“After years of rotating treatments and battling side effects, EliteAyurveda’s integrative regimen helped me find genuine, lasting relief. For the first time, I feel hopeful and in control.”

From the Doctor’s Desk

Dr. Adil Moulanchikkal, a renowned Ayurveda expert, says:

“Healing Psoriasis demands more than topical treatments. It calls for reestablishing the body’s balance, nurturing the mind, and cultivating resilience for genuine, enduring remission.”

With a rich background in Ayurvedic dermatology, Dr. Adil has guided numerous patients toward holistic rejuvenation and improved quality of life.

Your Journey to Healing Starts Here

Psoriasis doesn’t define your future. At EliteAyurveda, our Ayurvedic treatments pave the way for enduring transformation, targeting not just symptoms but the essence of health.

📞 Contact us today: +91 8884722246
Embrace the journey toward holistic healing and renewed confidence.

Related-

Know More About Ayurveda Treatment For Psoriasis

GET IN TOUCH

Schedule a Visit

Contact us

References

  • 1.World Health O. Global Report on Psoriasis. World Health Organization; Geneva, Switzerland: 2016. [Google Scholar]
  • 2.Griffiths C.E.M., Armstrong A.W., Gudjonsson J.E., Barker J. Psoriasis. Lancet. 2021;397:1301–1315. doi: 10.1016/S0140-6736(20)32549-6. [DOI] [PubMed] [Google Scholar]
  • 3.Armstrong A.W., Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323:1945–1960. doi: 10.1001/jama.2020.4006. [DOI] [PubMed] [Google Scholar]
  • 4.Kaushik S.B., Lebwohl M.G. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J. Am. Acad. Dermatol. 2019;80:27–40. doi: 10.1016/j.jaad.2018.06.057. [DOI] [PubMed] [Google Scholar]
  • 5.Reid C., Griffiths C.E.M. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm.-Venereol. 2020;100:adv00032. doi: 10.2340/00015555-3386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Singh A., Easwari T.S. Recent Advances in Psoriasis Therapy: Trends and Future Prospects. Curr. Drug Targets. 2021;22:1760–1771. doi: 10.2174/1389450122666210118103455. [DOI] [PubMed] [Google Scholar]
  • 7.Gyldenløve M., Alinaghi F., Zachariae C., Skov L., Egeberg A. Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review. Am. J. Clin. Dermatol. 2022;23:605–613. doi: 10.1007/s40257-022-00703-1. [DOI] [PubMed] [Google Scholar]
  • 8.Hsieh T.S., Tsai T.F. Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review. Dermatol. Ther. 2023;13:891–909. doi: 10.1007/s13555-023-00903-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Pourani M.R., Abdollahimajd F., Zargari O., Shahidi Dadras M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J. Dermatol. Treat. 2022;33:1967–1974. doi: 10.1080/09546634.2021.1966357. [DOI] [PubMed] [Google Scholar]
  • 10.Lwin S.M., Snowden J.A., Griffiths C.E.M. The promise and challenges of cell therapy for psoriasis. Br. J. Dermatol. 2021;185:887–898. doi: 10.1111/bjd.20517. [DOI] [PubMed] [Google Scholar]
  • 11.Salgado-Boquete L., Carrascosa J.M., Llamas-Velasco M., Ruiz-Villaverde R., de la Cueva P., Belinchón I. A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis? Life. 2021;11:627. doi: 10.3390/life11070627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C.E., Nast A., Franke J., Antoniou C., Arenberger P., Balieva F., et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch. Dermatol. Res. 2011;303:1–10. doi: 10.1007/s00403-010-1080-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Oranje A.P., Marcoux D., Svensson A., Prendiville J., Krafchik B., Toole J., Rosenthal D., de Waard-van der Spek F.B., Molin L., Axelsen M. Topical calcipotriol in childhood psoriasis. J. Am. Acad. Dermatol. 1997;36:203–208. doi: 10.1016/S0190-9622(97)70281-0. [DOI] [PubMed] [Google Scholar]
  • 14.Maul J.T., Anzengruber F., Conrad C., Cozzio A., Häusermann P., Jalili A., Kolios A.G.A., Laffitte E., Lapointe A.K., Mainetti C., et al. Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology. 2021;237:166–178. doi: 10.1159/000512930. [DOI] [PubMed] [Google Scholar]
  • 15.Elmets C.A., Korman N.J., Prater E.F., Wong E.B., Rupani R.N., Kivelevitch D., Armstrong A.W., Connor C., Cordoro K.M., Davis D.M.R., et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J. Am. Acad. Dermatol. 2021;84:432–470. doi: 10.1016/j.jaad.2020.07.087. [DOI] [PubMed] [Google Scholar]
  • 16.Blauvelt A., Leonardi C.L., Gooderham M., Papp K.A., Philipp S., Wu J.J., Igarashi A., Flack M., Geng Z., Wu T., et al. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156:649–658. doi: 10.1001/jamadermatol.2020.0723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Gold L.S., Lebwohl M.G., Sugarman J.L., Pariser D.M., Lin T., Martin G., Pillai R., Israel R., Ramakrishna T. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J. Am. Acad. Dermatol. 2018;79:287–293. doi: 10.1016/j.jaad.2018.03.040. [DOI] [PubMed] [Google Scholar]
  • 18.Lis-Święty A., Frątczak A. Proactive therapy: New perspectives for long-term topical treatment of psoriasis. Dermatol. Ther. 2022;35:e15364. doi: 10.1111/dth.15364. [DOI] [PubMed] [Google Scholar]
  • 19.Soleymani T., Hung T., Soung J. The role of vitamin D in psoriasis: A review. Int. J. Dermatol. 2015;54:383–392. doi: 10.1111/ijd.12790. [DOI] [PubMed] [Google Scholar]
  • 20.Amiri D., Schwarz C.W., Gether L., Skov L. Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review. Acta Derm.-Venereol. 2023;103:adv00890. doi: 10.2340/actadv.v103.6525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Fritz K., Salavastru C. The 308 nm Excimer laser for the treatment of psoriasis and inflammatory skin diseases. Der Hautarzt Z. Dermatol. Venerol. Verwandte Geb. 2018;69:35–43. doi: 10.1007/s00105-017-4105-2. [DOI] [PubMed] [Google Scholar]
  • 22.Menter A., Strober B.E., Kaplan D.H., Kivelevitch D., Prater E.F., Stoff B., Armstrong A.W., Connor C., Cordoro K.M., Davis D.M.R., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 2019;80:1029–1072. doi: 10.1016/j.jaad.2018.11.057. [DOI] [PubMed] [Google Scholar]
  • 23.Menter A., Gelfand J.M., Connor C., Armstrong A.W., Cordoro K.M., Davis D.M.R., Elewski B.E., Gordon K.B., Gottlieb A.B., Kaplan D.H., et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J. Am. Acad. Dermatol. 2020;82:1445–1486. doi: 10.1016/j.jaad.2020.02.044. [DOI] [PubMed] [Google Scholar]
  • 24.Elmets C.A., Lim H.W., Stoff B., Connor C., Cordoro K.M., Lebwohl M., Armstrong A.W., Davis D.M.R., Elewski B.E., Gelfand J.M., et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J. Am. Acad. Dermatol. 2019;81:775–804. doi: 10.1016/j.jaad.2019.04.042. [DOI] [PubMed] [Google Scholar]
  • 25.Lambert J.L.W., Segaert S., Ghislain P.D., Hillary T., Nikkels A., Willaert F., Lambert J., Speeckaert R. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1) J. Eur. Acad. Dermatol. Venereol. JEADV. 2020;34:1654–1665. doi: 10.1111/jdv.16684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Armstrong A.W., Puig L., Joshi A., Skup M., Williams D., Li J., Betts K.A., Augustin M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020;156:258–269. doi: 10.1001/jamadermatol.2019.4029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kimball A.B., Rothman K.J., Kricorian G., Pariser D., Yamauchi P.S., Menter A., Teller C.F., Aras G., Accortt N.A., Hooper M., et al. OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J. Am. Acad. Dermatol. 2015;72:115–122. doi: 10.1016/j.jaad.2014.08.050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Menter A., Thaçi D., Wu J.J., Abramovits W., Kerdel F., Arikan D., Guo D., Ganguli A., Bereswill M., Camez A., et al. Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. Dermatol. Ther. 2017;7:365–381. doi: 10.1007/s13555-017-0198-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kalb R.E., Fiorentino D.F., Lebwohl M.G., Toole J., Poulin Y., Cohen A.D., Goyal K., Fakharzadeh S., Calabro S., Chevrier M., et al. Risk of Serious Infection with Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) JAMA Dermatol. 2015;151:961–969. doi: 10.1001/jamadermatol.2015.0718. [DOI] [PubMed] [Google Scholar]

Related Posts:

RELATED ARTICLESMORE FROM AUTHOR